Twist Bioscience (NASDAQ: TWST) Demonstrates Strong Revenue Growth Despite Earnings Miss

• Twist Bioscience (NASDAQ: TWST) reported a wider-than-expected loss of $0.56 per share for the quarter, missing analyst estimates.
• Despite the earnings miss, the company achieved strong revenue of $118.4 million, marking its 14th consecutive quarter of revenue growth with a 23% year-over-year increase.
• The biotechnology firm exhibits a healthy Debt-to-Equity ratio of 0.21 and a Current Ratio of 2.67, though its Price-to-Earnings (P/E) ratio of -45.52 reflects current unprofitability.

Twist Bioscience (NASDAQ: TWST) is a life sciences company that manufactures synthetic DNA for various applications. It operates in the medical, biomedical, and genetics industry. The company provides tools for clients in drug discovery, agricultural biology, and industrial chemicals, with a growing focus on AI-enabled discovery.

On August 3, 2026, Twist Bioscience announced its quarterly earnings. The company reported a loss of $0.56 per share, which was wider than the consensus estimate. As highlighted by Zacks, this figure missed their estimate of a $0.50 loss per share and was also greater than the $0.47 loss from the same period last year.

Despite the earnings miss, Twist Bioscience reported strong revenue of $118.4 million for the quarter. This amount surpassed the estimated $114.55 million. This marks a 23% increase from the previous year and represents the company's 14th straight quarter of revenue growth, showing consistent demand for its biotechnology products.

The revenue growth is driven by strong performance across its business segments. Revenue from DNA Synthesis and Protein Solutions increased by 39% year over year to $56.6 million. Its Next-Generation Sequencing (NGS) Applications revenue also grew by 12% to approximately $61.8 million during the same period.

The company's financial health shows a low Debt-to-Equity ratio of 0.21, indicating that it does not rely heavily on debt. Its current ratio of 2.67 suggests that it has enough short-term assets to cover its short-term debts. However, its Price-to-Earnings (P/E) ratio of -45.52 is negative, reflecting its current unprofitability.